Ultrasensitive flow-based immunoassays using single-molecule counting.

BACKGROUND Immunoassay (IA) technology has expanded the clinical utility of protein biomarkers, but demands for increased sensitivity, dynamic reporting ranges, and small sample volumes have limited the potential clinical usefulness of many biomarkers. We assessed the performance, including limits of detection (LODs) and the dynamic reporting range, of an IA-based technology, Erenna Immunoassay System, for a series of biomarkers, including cardiac troponin I (cTnI). METHODS Erenna IAs were used with 10 different and clinically important biomarkers to ascertain the LOD with various sample sizes (10 microL to 200 microL). RESULTS The Erenna Immunoassay System generated LODs of 10-100 pg/L using 100 microL of sample. For cTnI, the LOD was 0.2 ng/L and a 10% CV was seen between 0.78 and 1.6 ng/L. CONCLUSIONS The Erenna IA-based technology reproducibly measures protein biomarkers with detection limits of 10-100 pg/L, with a dynamic range of >4.5 logs in sample volumes of 50-150 microL.

[1]  S. Dhawan,et al.  Signal amplification systems in immunoassays: implications for clinical diagnostics , 2006, Expert review of molecular diagnostics.

[2]  T. Toyo-Oka,et al.  Cardiac troponin levels as a preferable biomarker of myocardial cell degradation. , 2007, Advances in experimental medicine and biology.

[3]  R. Banks.  Measurement of Cytokines in Clinical Samples Using Immunoassays: Problems and Pitfalls , 2000, Critical reviews in clinical laboratory sciences.

[4]  J. Schüpbach.  Viral RNA and p24 Antigen as Markers of HIV Disease and Antiretroviral Treatment Success , 2003, International Archives of Allergy and Immunology.

[5]  W. Hogrefe.  Biomarkers and assessment of vaccine responses , 2005, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[6]  F. Dunn,et al.  Serological evidence of early remodeling in high-risk non-ST elevation acute coronary syndromes. , 2008, International journal of cardiology.

[7]  C T Lim,et al.  Bead-based microfluidic immunoassays: the next generation. , 2007, Biosensors & bioelectronics.

[8]  P. O'Brien.  Blood cardiac troponin in toxic myocardial injury: archetype of a translational safety biomarker , 2006, Expert review of molecular diagnostics.

[9]  D. Seligson,et al.  Clinical Chemistry , 1965, Bulletin de la Societe de chimie biologique.

[10]  S. Lehmann,et al.  Protein biochip systems for the clinical laboratory , 2005, Clinical chemistry and laboratory medicine.

[11]  A. Wu,et al.  Development and preliminary clinical validation of a high sensitivity assay for cardiac troponin using a capillary flow (single molecule) fluorescence detector. , 2006, Clinical chemistry.

[12]  M. Meriggioli.  Use of immunoassays in neurological diagnosis and research , 2005, Neurological research.

[13]  X Chris Le,et al.  Assays for cytokines using aptamers. , 2006, Methods.

[14]  Klabusay Martin,et al.  Simultaneous Analysis of Cytokines and Costimulatory Molecules Concentrations by ELISA Technique and of Probabilities of Measurable Concentrations of Interleukins IL-2, IL-4, IL-5, IL-6, CXCL8 (IL-8), IL-10, IL-13 Occurring in Plasma of Healthy Blood Donors , 2006, Mediators of inflammation.